Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter to Buy Remainder of NexGen

NEW YORK (GenomeWeb News) – Beckman Coulter said yesterday it has agreed to buy the remaining 80.1 percent of NexGen Diagnostics, a spin-out of Lumigen, which it bought in late 2006 for $185 million. 
NexGen owns intellectual property that Beckman Coulter hopes to use for immunoassay and nucleic acid-based diagnostic testing.
Because NexGen’s assets are in the form of intellectual property that will require development, Beckman Coulter said it expects to take a charge of around $36 million for in-process R&D after the deal closes in the fourth quarter of 2007.
The IP is centered on a non-separation immunoassay technology that cuts out “time-consuming steps,” Beckman said, adding that it allows “rapid isolation of DNA or RNA from a patient sample without a separate step or reagent.”
Financial terms of the agreement were not released.
The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.